Cassava Sciences Inc (SAVA)
$23.12
1.56 (7.24%)
SAVA Stock Quote Delayed 30 Minutes
SAVA Stock Alert: What Is Going on With Red-Hot Cassava Sciences Today?
Biotech company Cassava saw a big jump today on positive news related to its Alzheimer's disease treatment. Keep an eye on SAVA stock.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
970.35M
PE Ratio
-36.70
EPS
-0.63
Volume (Avg. Vol.)
774,568
Day's Range
$21.36 - $23.39
52-Week Range
$12.32 - $32.10
Dividend & Yield
N/A (N/A)
SAVA Stock Predictions, Articles, and Cassava Sciences Inc News
Cassava Sciences Just Returned to the Buy Zone
There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease.
SAVA Stock Alert: The SEC Investigation That Has Cassava Sciences Cratering Today
Cassava Sciences (SAVA) stock is on the move Wednesday as investors react to reports of an SEC investigation over possible data manipulation.
Cassava Sciences Needs Time and Data to Prove Itself Before You Buy
Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever.
Cassava Is a Sell After Accusations of Data Manipulation
After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock.
Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop
Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.
SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today
Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations.
Cassava Sciences Is on a Bumpy Road to Multibagger Status
Based on analyst estimates for the next ten years, SAVA stock could be worth three times more if its Alzheimer's drug succeeds.
Cassava Stock Could Jump More Than 200 Times
Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock.
Cassava Sciences’ Stock Remains an Enigma
Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run. It did the opposite.
Buy SAVA Stock on Dips as its Phase 3 Trial Moves Along
There's no way to mitigate its high risk nature completely. But if you're bullish on Simulfilam? Buying SAVA stock on weakness, between now and when the data from its Phase 3 trial starts rolling in, may be the best move.
Cassava Sciences: Fine Trading Stock, Terrible Investment
SAVA stock has fallen sharply in recent weeks. However, it's still a rather expensive bet on a controversial drug heading into Phase 3 trials.
Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility
SAVA stock is volatile but worthwhile as its Alzheimer's drug inches closer to commercialization. Risk tolerance is needed, but likely smart
SAVA Stock Is a Buy Here Despite the Very Real Risks It Faces
Like with any biotech situation, where it's big possible gains against large possible losses, caution is key. But for investors who approach SAVA stock accordingly, and are able to ride out any future near-term dips in price? It may be a gamble worth taking.
Use Cassava Sciences Stock Weakness as Buy Opportunity Ahead of Phase 3
If Cassava Sciences' Alzheimer drug can continue to produce solid results, it could see FDA approval before the end of 2022. SAVA stock may not be oversold for long.
What to Make of Cassava Sciences’ Late September Rally
Cassava Sciences gained 50% in the second half of September. Now the question is, can SAVA stock keep up momentum in October?
Cassava Stock Has Reached a Positive Turning Point
Cassava is rebounding and SAVA stock may rally back to its old highs as it fends off a short-selling attack.
The Good News Is Piling Up for Cassava Stock
Recent news indicates that the FDA is going to reject a petition against Cassava, helping to make SAVA stock very attractive.
SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?
Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off.
